Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 227-235

  Doi, Toshihiko ^a   Ohtsu, Atsushi ^a   Fuse, Nozomu ^a   Yoshino, Takayuki ^a   Tahara, Makoto ^a   Shibayama, Kazuhiro ^b   Takubo, Takatoshi ^b   Weinreich, David M ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Takeda Bio Development Center Ltd   (Japan)

^c AMGEN INC   (United States)

Author keywords

AMG 386; Angiopoietin 1 2 neutralizing peptibody; Clinical trial, phase 1; Pharmacokinetics; Safety; Trebananib

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; TREBANANIB;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; BINDING AFFINITY; BINDING SITE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CHOLECYSTITIS; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RECTUM CANCER; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS CANCER; VEIN THROMBOSIS;

ADULT; AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84872326846     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2000-1     Document Type: Article

References (24)

1. Fidler IJ, Kerbel RS, Ellis LM (2001) Biology of cancer: angiogenesis. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven Publishers, Philadelphia, pp 137-147
2. Leek RD (2001) The prognostic role of angiogenesis in breast cancer. Anticancer Res 21:4325-4331
3. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395
4. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906-3927
5. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
6. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
7. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X (2007) Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2:59-71
8. Eskens FA, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 42:3127-3139
9. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143
10. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J (2001) Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159:2271-2280
11. Bach F, Uddin FJ, Burke D (2007) Angiopoietins in malignancy. Eur J Surg Oncol 33:7-15
12. Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
13. Ahmad SA, Liu W, Jung YD et al (2001) The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255-1259
14. Coxon A, Bready J, Min H et al (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9:2641-2651
15. Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6:507-516
16. Herbst RS, Hong D, Chap L et al (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27:3557-3565
17. Mita AC, Takimoto CH, Mita M et al (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16:3044-3056
18. Zhong ZD, Dinnogen S, Hokom M et al (2010) Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods 355:21-28
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92:205-216
20. Karlan BY, Oza AM, Richardson GE et al (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30:362-371
21. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
22. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
23. Hecht JR, Trarbach T, Hainsworth JD et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003
24. Robson EJ, Ghatage P (2011) AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 20:297-304